Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Pharma Files IND for New Anti-Hypertensive Drug

publication date: Mar 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharmaceutical announced its application to begin clinical trials of a new treatment for hypertension was accepted by the SFDA. The company developed Tylerdipine Hydrochloride, a calcium channel blocker, in its own facilities. Sihuan hopes to obtain approval to begin the China trials by the end of 2013, and the company will also seek to run tests of the product in the US. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors